[CONTENTS 002 IMPORTANT NOTICE 003 CORPORATE PROFILE 006 SUMMARY OF FINANCIAL DATA AND FINANCIAL INDICATORS 009 CHANGES IN SHAREHOLDINGS AND INFORMATION ON SHAREHOLDERS 015 CHAIRMANS REPORT 018 BUSINESS REVIEW 024 DISCUSSION AND ANALYSIS OF OPERATIONS 037 SIGNIFICANT EVENTS 045 CONNECTED TRANSACTION]
[This Form 6-K consists of: Notice of Board Meeting Board Sinopec Corp. This is to announce that a meeting of the board of directors (the “ By Order of the Board China Petroleum & Chemical Corporation Huang Wensheng Vice President and Secretary to the Board of Directors Beijing, the PRC, 15 April 201]
[Sinovac Announces Positive Results From Phase III Trial Of a Sabin Strain-Based Inactivated Polio Vaccine (sIPV) Published in the Journal of Infectious Disease · The Sinovac-developed sIPV demonstrates both long-term affordability and accessibility and has the potential to contribute significantly t]
[CONTENTS 002 IMPORTANT NOTICE 003 CORPORATE PROFILE 006 SUMMARY OF FINANCIAL DATA AND FINANCIAL INDICATORS 009 CHANGES IN SHAREHOLDINGS AND INFORMATION ON SHAREHOLDERS 015 CHAIRMANS REPORT 018 BUSINESS REVIEW 024 DISCUSSION AND ANALYSIS OF OPERATIONS 037 SIGNIFICANT EVENTS 045 CONNECTED TRANSACTION]
[NONE (Title of Class) _______________________ NONE (Title of Class) _______________________ Indicate the number of outstanding shares of each of the issuer's classes of capital or common stock as of the close of the period covered by the annual report: Domestic A Shares with Par Value of RMB1.00 Per]
[Sinovac Announces Positive Results From Phase III Trial Of a Sabin Strain-Based Inactivated Polio Vaccine (sIPV) Published in the Journal of Infectious Disease · The Sinovac-developed sIPV demonstrates both long-term affordability and accessibility and has the potential to contribute significantly t]
[ANNOUNCEMENT ON KEY OPERATING DATA The relevant key operating data was calculated based on the internal statistics of the Group, which may differ from the data disclosed in the relative periodic reports. Investors are hereby reminded of the risks which may result from inappropriate reliance upon or ]
[NONE (Title of Class) _______________________ NONE (Title of Class) _______________________ Indicate the number of outstanding shares of each of the issuer's classes of capital or common stock as of the close of the period covered by the annual report: Domestic A Shares with Par Value of RMB1.00 Per]
